Intraindividual and interindividual variabilities in endogenous cortisol 66β-hydroxylation clearance as an index for in vivo cyp3a phenotyping in humans

Drug Metabolism and Disposition

Volumn 41, Issue 2, 2013, Pages 475-479

  Shibasaki, Hiromi ^a   Hosoda, Kaori ^b   Goto, Mari ^a   Suzuki, Atsushi ^a   Yokokawa, Akitomo ^a   Ishii, Kazuo ^b   Furuta, Takashi ^a  

^a TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES   (Japan)

^b KYORIN UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

6BETA HYDROXYHYDROCORTISONE; CYTOCHROME P450 3A;

ADULT; ARTICLE; CIRCADIAN RHYTHM; CLEARANCE; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN EXPERIMENT; IN VIVO STUDY; JAPANESE; MALE; NORMAL HUMAN; PHENOTYPE; PRIORITY JOURNAL; SEX DIFFERENCE;

ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; BIOLOGICAL MARKERS; BIOTRANSFORMATION; CIRCADIAN RHYTHM; CYTOCHROME P-450 CYP3A; FEMALE; HUMANS; HYDROCORTISONE; HYDROXYLATION; JAPAN; KINETICS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; PHENOTYPE; SEX FACTORS; SUBSTRATE SPECIFICITY; YOUNG ADULT;

EID: 84872727527     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.112.048561     Document Type: Article

References (28)

1. Bruguerolle B (1998) Chronopharmacokinetics. Current status. Clin Pharmacokinet 35: 83-94.
2. Cotreau MM, von Moltke LL, and Greenblatt DJ (2005) The influence of age and sex on the clearance of cytochrome P450 3A substrates. Clin Pharmacokinet 44:33-60. (Pubitemid 40100551)
3. Dahl M-L (2002) Cytochrome p450 phenotyping/genotyping in patients receiving antipsychotics: useful aid to prescribing? Clin Pharmacokinet 41:453-470. (Pubitemid 34804159)
4. Draper N and Stewart PM (2005) 11b-hydroxysteroid dehydrogenase and the pre-receptor regulation of corticosteroid hormone action. J Endocrinol 186:251-271. (Pubitemid 41167396)
5. Furuta T, Eguchi N, Shibasaki H, and Kasuya Y (2000a) Simultaneous determination of endogenous and 13C-labelled cortisols and cortisones in human plasma by stable isotope dilution mass spectrometry. J Chromatogr B Biomed Sci Appl 738:119-127. (Pubitemid 30053099)
6. Furuta T, Eguchi N, Yokokawa A, Shibasaki H, and Kasuya Y (2000b) Synthesis of multi-labeled cortisols and cortisones with 2H and 13C for study of cortisol metabolism in humans. Steroids 65:180-189. (Pubitemid 30129251)
7. Furuta T, Mori C, Suzuki A, Shibasaki H, Yokokawa A, and Kasuya Y (2004) Simultaneous determination of 6b-hydroxycortisol and cortisol in human urine by liquid chromatography with ultraviolet absorbance detection for phenotyping the CYP3A activity determined by the cortisol 6b-hydroxylation clearance. J Chromatogr B Analyt Technol Biomed Life Sci 801: 165-171. (Pubitemid 38130065)
8. Furuta T, Okamiya K, Shibasaki H, and Kasuya Y (1996) Pharmacokinetics of stable isotopically labeled L-histidine in humans and the assessment of in vivo histidine ammonia lyase activities. Drug Metab Dispos 24:49-54. (Pubitemid 26028384)
9. Furuta T, Suzuki A, Mori C, Shibasaki H, Yokokawa A, and Kasuya Y (2003) Evidence for the validity of cortisol 6 b-hydroxylation clearance as a new index for in vivo cytochrome P450 3A phenotyping in humans. Drug Metab Dispos 31:1283-1287. (Pubitemid 37310312)
10. Furuta T, Suzuki A, Shibasaki H, Yokokawa A, and Kasuya Y (2001) Urinary 6bhydroxycortisol/cortisol ratio does not reflect in vivo CYP3A activity in humans [in Japanese]. Nihon Yakubutsu Dotai Gakkai 16:S98-S99.
11. Galteau MM and Shamsa F (2003) Urinary 6b-hydroxycortisol: a validated test for evaluating drug induction or drug inhibition mediated through CYP3A in humans and in animals. Eur J Clin Pharmacol 59:713-733. (Pubitemid 38041296)
12. Ged C, Rouillon JM, Pichard L, Combalbert J, Bressot N, Bories P, Michel H, Beaune P, and Maurel P (1989) The increase in urinary excretion of 6 b-hydroxycortisol as a marker of human hepatic cytochrome P450IIIA induction. Br J Clin Pharmacol 28:373-387. (Pubitemid 19269774)
13. Harris RZ, Benet LZ, and Schwartz JB (1995) Gender effects in pharmacokinetics and pharmacodynamics. Drugs 50:222-239.
14. Horsmans Y, Desager JP, and Harvengt C (1992) Absence of CYP3A genetic polymorphism assessed by urinary excretion of 6 b-hydroxycortisol in 102 healthy subjects on rifampicin. Pharmacol Toxicol 71:258-261.
15. Inagaki K, Inagaki M, Kataoka T, Sekido I, Gill MA, and Nishida M (2002) A wide interindividual variability of urinary 6b-hydroxycortisol to free cortisol in 487 healthy Japanese subjects in near basal condition. Ther Drug Monit 24:722-727. (Pubitemid 35379525)
16. Lutz U, Bittner N, Ufer M, and Lutz WK (2010) Quantification of cortisol and 6 b-hydroxycortisol in human urine by LC-MS/MS, and gender-specific evaluation of the metabolic ratio as biomarker of CYP3A activity. J Chromatogr B Analyt Technol Biomed Life Sci 878: 97-101.
17. Micuda S, Sispera L, Hodac M, Parízek P, Fuksa L, Brcáková E, Cerman J, Cermanová J, and Martí nková J (2007) Diurnal variation of 6b-hydroxycortisol in cardiac patients. Physiol Res 56:307-313.
18. Monsarrat B, Chatelut E, Royer I, Alvinerie P, Dubois J, Dezeuse A, Roche H, Cros S, Wright M, and Canal P (1998) Modification of paclitaxel metabolism in a cancer patient by induction of cytochrome P450 3A4. Drug Metab Dispos 26:229-233. (Pubitemid 28182398)
19. Ohno M, Yamaguchi I, Ito T, Saiki K, Yamamoto I, and Azuma J (2000) Circadian variation of the urinary 6b-hydroxycortisol to cortisol ratio that would reflect hepatic CYP3A activity. Eur J Clin Pharmacol 55:861-865. (Pubitemid 30201769)
20. Peng C-C, Templeton I, Thummel KE, Davis C, Kunze KL, and Isoherranen N (2011) Evaluation of 6b-hydroxycortisol, 6b-hydroxycortisone, and a combination of the two as endogenous probes for inhibition of CYP3A4 in vivo. Clin Pharmacol Ther 89: 888-895.
21. Pichard-Garcia L, Hyland R, Baulieu J, Fabre J-M, Milton A, and Maurel P (2000) Human hepatocytes in primary culture predict lack of cytochrome P-450 3A4 induction by eletriptan in vivo. Drug Metab Dispos 28:51-57. (Pubitemid 30027512)
22. Shibasaki H, Okamoto S, Inoue R, Okita M, Yokokawa A, and Furuta T (2012) Separation and quantitative determination of 6a-hydroxycortisol and 6b-hydroxycortisol in human urine by high-performance liquid chromatography with ultraviolet absorption detection. Anal Bioanal Chem 402:2945-2952.
23. Streetman DS, Bertino JS, Jr., and Nafziger AN (2000) Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes. Pharmacogenetics 10:187-216. (Pubitemid 30242736)
24. Watkins PB (1994) Noninvasive tests of CYP3A enzymes. Pharmacogenetics 4:171-184. (Pubitemid 24269821)
25. Wilkinson GR (1996) Cytochrome P4503A (CYP3A) metabolism: prediction of in vivo activity in humans. J Pharmacokinet Biopharm 24:475-490. (Pubitemid 27156933)
26. Yin OQ, Shi X, Tomlinson B, and Chow MS (2004) Interindividual and intraindividual variability of the urinary 6b-hydroxycortisol/cortisol ratio in Chinese subjects: implications of its use for evaluating CYP3A activity. J Clin Pharmacol 44:1412-1417. (Pubitemid 39518648)
27. Zaigler M, Tantcheva-Poór I, and Fuhr U (2000) Problems and perspectives of phenotyping for drug-metabolizing enzymes in man. Int J Clin Pharmacol Ther 38:1-9. (Pubitemid 30048654)
28. Zhu B, Liu Z-Q, Chen G-L, Chen X-P, Ou-Yang D-S, Wang L-S, Huang S-L, Tan Z-R, and Zhou H-H (2003) The distribution and gender difference of CYP3A activity in Chinese subjects. Br J Clin Pharmacol 55:264-269. (Pubitemid 36390756)